Allergy

Biosimilars

Cardiology

Dermatology

Endocrinology

Family Medicine

Gastroenterology

Geriatrics

Hospital Medicine

Infectious Disease

Internal Medicine

Nephrology

Neurology

Obesity Management

Ophthalmology

Pain

Pediatrics

Psychiatry

Pulmonology

Rare Disease Report®

Rheumatology

Sleep

Surgery

Women's Health

News

Media

Medical World News

Podcasts

Shows

State Of Sciences - Presentations

Videos

Webinars

Multimedia Series

Insights

Medcast Podcasts

Medcast Videos

Peer Exchange

Peers & Perspectives

Conferences

Conference Coverage

Conference Listing

Partners

CME/CE

Resources

Interactive Tools

Live Events

Press Release

Publications

Subscribe

Lana Dykes is the editor of HCPLive Rheumatology. She is an experienced editor and technical writer with a demonstrated history of working in the banking and publishing industries. In her free time, she enjoys cooking, yoga, listening to podcasts, and drawing. She can be reached via email at LDykes@mjhlifesciences.com.

Articles

The January 2023 rheumatology month in review highlights a recent study that indicated an increased risk of hospitalization and death among patients with gout and COVID-19, the expansion of research evaluating adalimumab biosimilars, and trends in fibromyalgia. 





Rheumatology Month in Review: January 2023 

An FDA panel voted unanimously this week to support harmonizing an annual primary and booster dose, moving public health strategies to reflect the endemic course of COVID-19.

Our COVID-19 Vaccine Expectations Are Finally Getting Realistic

Connor Iapoce is an associate editor for 

 and joined the MJH Life Sciences team in April 2021. He graduated from The College of New Jersey with a degree in Journalism and Professional Writing. He enjoys listening to records, going to concerts, and playing with his cat Squish. You can reach him at 

A lower DME resolution rate was associated with a thicker baseline CST and better baseline best-corrected visual acuity in eyes treated with aflibercept. 

Thicker Baseline CST Linked to Longer DME Resolution in Aflibercept-Treated Eyes

A new review shows a majority of COVID-19 randomized, controlled trial preprints have been published with changes to the components of the original findings.

COVID-19 Preprint Studies Take About 6 Months to Publish

HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care to patients. At HCPLive, you will find breaking news, video interviews with physician experts, in-depth conference coverage, finance and practice management updates, insight and analysis from physician contributors, and more.

About Us

Advertise

Editorial

Contact Us

Do Not Sell My Information

Privacy

Terms & Conditions

HCPLive - Clinical news for connected physicians

Facebook

Twitter

LinkedIn

Spotlight

Biosimilars Spotlight

COVID-19

Qazi Corner

This Year In Medicine 2022

Clinical

ADHD

Arterial Disease

Diabetes

Geriatric Medicine

Video Series

News Network

Post Conference Perspectives

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Clinical Topics

Type 1 Diabetes

A study of more than 100 adults with type 1 diabetes suggests those with increased levels of self-stigma had worse glucose control than their counterparts with lower levels of self-stigma.

Self-Stigma Could Contribute to Worsening Glucose Control in Type 1 Diabetes

Abbott's Proclaim XR spinal cord stimulation system allows patients with painful diabetic peripheral neuropathy to improve quality of life using a system that is easily incorporated into their everyday lives.

FDA Approves Proclaim XR Spinal Cord Stimulation for Painful Diabetic Peripheral Neuropathy 

Announced on January 24, the US FDA's marketing clearance for the Tidepool Loop mobile app allows for use with compatible devices for automated insulin dosing to help manage type 1 diabetes in persons 6 years of age and older.

Tidepool Loop Mobile App Receives FDA Marketing Clearance

A prospective, dual-center study of people with high-risk type 1 diabetes using multiple daily injections aged 13-25 years demonstrates the utility of this technology in this patient population. 

Advanced Hybrid Closed Loop System Could Improve Glucose Control in Youth with High-Risk Type 1 Diabetes

Type 1 Diabetes

Latest News